Sirolimus and Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma

Filip Janku, MD, PhD, assistant professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, discusses a trial presented at the 2014 ASCO Annual Meeting looking at the activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated patients with refractory Hodgkin lymphoma. Researchers concluded that this combination of agents was well tolerated and demonstrated encouraging activity.

<<<

Back to the ASCO 2014 conference page